title: Topical diacerein for epidermolysis bullosa: a randomized controlled pilot study.
abstract: Blistering in epidermolysis bullosa simplex type Dowling-Meara (EBS-DM) is associated with an inflammatory phenotype, which can be disrupted by diacerein in vitro. In this pilot study we hypothesized, that a topical formulation of diacerein 1% reduces blistering. Five patients initially applied diacerein underneath both armpits. Then, each participant received 1% diacerein-cream for one armpit, and placebo for the other (randomized withdrawal). The number of blisters was reduced significantly (left: -78%; right: -66% of baseline) within two weeks and remained significantly below the initial level even during withdrawal in four patients. These findings point to a relevant effect of diacerein and provide important information for a confirmative study.
authors: Division of Experimental Dermatology and EB House Austria, Department of Dermatology, Paracelsus Medical University Salzburg, Muellner Hauptstraße 48, Salzburg 5020, Austria. v.wally@salk.at
authors: Verena
authors: V
authors: Wally
authors: Sophie
authors: S
authors: Kitzmueller
authors: Florian
authors: F
authors: Lagler
authors: Angelika
authors: A
authors: Moder
authors: Wolfgang
authors: W
authors: Hitzl
authors: Martin
authors: M
authors: Wolkersdorfer
authors: Peter
authors: P
authors: Hofbauer
authors: Thomas K
authors: TK
authors: Felder
authors: Michael
authors: M
authors: Dornauer
authors: Anja
authors: A
authors: Diem
authors: Nora
authors: N
authors: Eiler
authors: Johann W
authors: JW
authors: Bauer
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000880:Anthraquinones / Q000008:administration & dosage / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001768:Blister / Q000188:drug therapy; D002648:Child; D004311:Double-Blind Method; D016110:Epidermolysis Bullosa Simplex / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D053547:Keratin-14 / Q000235:genetics; D008875:Middle Aged; D010865:Pilot Projects; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000880:Anthraquinones; D000893:Anti-Inflammatory Agents; C507540:KRT14 protein, human; D053547:Keratin-14; C025292:diacerein
references: Osteoarthritis Cartilage. 2000 May;8(3):186-96
references: 10806046
references: J Invest Dermatol. 2013 Jul;133(7):1901-3
references: 23344459
references: Br J Dermatol. 2003 Jul;149(1):46-58
references: 12890194
references: J Clin Invest. 2009 Jul;119(7):1784-93
references: 19587453
references: Rheumatology (Oxford). 2006 Feb;45(2):129-38
references: 16278282